MPL and autoimmune thrombocytopenic purpura: On the other hand, the inhibitory effect of anti-platelet autoantibodies associated with immune thrombocytopenia (ITP) on platelet production has also been clearly documented [109,110], explaining the benefits of treating patients with chronic ITP with thrombopoietin receptor agonists.